目的 分析新疆精神卫生中心抗抑郁药的使用情况及发展趋势，为抗抑郁药物的合理使用提供参考依据。方法 对新疆精神卫生中心2023—2025年使用抗抑郁药的销售金额、用药频度（DDDs）、限定日费用（DDC）及排序比（B/A）进行分析。结果 3年间，新疆精神卫生中心抗抑郁药销售额呈下降趋势，DDDs呈持续上升趋势，这一现象反映出，在集中采购政策下，尽管抗抑郁药物的临床使用频度增加，药品费用却呈现出了下降。艾司西酞普兰销售额排名第1位，DDDs前5位中除文拉法辛外其余均为选择性5-羟色胺（5-HT）再摄取抑制剂（SSRIs），大部分药物的DDC呈下降趋势。结论 新疆精神卫生中心抗抑郁药物的临床使用合理，选择性5-羟色胺再摄取抑制剂（SSRIs）与选择性5-羟色胺和去甲肾上腺素再摄取抑制剂（SNRIs）两类药物占据主导地位。

Objective To analyze the clinical application and developing trend of antidepressants in Xinjiang Mental Health Center, so as to provide a reference for the rational use of antidepressants. Methods the consumption sum, DDDs, DDC,B/A of antidepressants used in the center from 2023 to 2025 were analyzed. Results Over a period of three years, the sales of antidepressant drugs at the Xinjiang Mental Health Center showed a downward trend, while the DDDs continued to rise. This phenomenon indicates that under the centralized procurement policy, although the clinical usage frequency of antidepressant drugs has increased, the drug costs have shown a decline. Escitalopram ranked first in terms of sales, and among the top 5 DDDs, all except venlafaxine were selective 5-HT SSRIs. The DDC of most drugs showed a downward trend. Conclusion The application of antidepressants in the center is basically reasonable with selective serotonin reuptake inhibitors (SSRIs) and selective serotonin-norepinephrine reuptake inhibitors (SNRIs) dominating as major drug categories.

R971

乌鲁木齐市卫生健康委科技计划项目（202317）